Balyasny Asset Management
XLRN

Balyasny Asset Management’s Acceleron Pharma XLRN Stock Holding History

Balyasny Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-105,000
Closed -$18.1M – 2767
2021
Q3 		$18.1M Buy
+105,000
New +$13.7M 0.08% 373

Balyasny Asset Management's XLRN Position: Q4 2021 in Review

Balyasny Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 140,492 shares — an estimated $24.2M sold.

Balyasny Asset Management first reported a position in XLRN in Q4 2017 and held it in 4 quarters. The position peaked at $24.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Balyasny Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Balyasny Asset Management sold 140,492 Acceleron Pharma shares in Q4 2021, an estimated $24.2M.
  • Balyasny Asset Management first reported a position in Acceleron Pharma in Q4 2017 and held it in 4 quarters.
  • Balyasny Asset Management's Acceleron Pharma position peaked at $24.2M in Q3 2021.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.